Land: Südafrika
Sprache: Englisch
Quelle: South African Health Products Regulatory Authority (SAHPRA)
Dr-reddy
LITARES (film-coated tablets) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): LITARES (film-coated tablets) COMPOSITION LITARES: Each film-coated tablet contains moxifloxacin hydrochloride equivalent to moxifloxacin 400 mg Sugar free PHARMACOLOGICAL CLASSIFICATION A 20.1.1 Broad and medium spectrum antibiotics PHARMACOLOGICAL ACTION Moxifloxacin is a fluoroquinolone antibacterial with a broad spectrum of bactericidal action. Moxifloxacin has been shown to be active in vitro against most of the following microorganisms listed below. In vitro sensitivity may not always have been confirmed in clinical infection (see INDICATIONS). Microbiology Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination. There is no known cross-resistance between moxifloxacin and other classes of antimicrobials. Cross-resistance has been observed between moxifloxacin and other fluoroquinolones against Gram-negative bacteria. Gram-positive bacteria resistant to other fluoroquinolones may, however, still be susceptible to moxifloxacin. Moxifloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described under INDICATIONS AND DOSAGE AND DIRECTIONS FOR USE. Aerobic Gram-positive microorganisms Staphylococcus aureus (methicillin-susceptible strains only) Streptococcus pneumoniae (penicillin-susceptible strains) Aerobic Gram-negative microorganisms Haemophilus influenzae Haemophilus parainfluenzae Klebsiella pneumoniae Moraxella catarrhalis Other microorganisms Chlamydia pneumoniae Mycoplasma pneumoniae The following in Lesen Sie das vollständige Dokument